Clinical Trial

Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients

Name: Befotertinib Adjuvant Therapy in Stage IA2-IB NSCLC Patients — clinical trial record (NCT06561620)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 4

View on ClinicalTrials.gov →

Summary

To evaluate 3-year disease-free survival after complete resection in patients with MRD-positive EGFR-sensitive mutations in Stage IA2-IB NSCLC treated with adjuvant befortinib and under routine observation (3y-DFS).

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2024-08-16.

Trial Details

NCT Number	NCT06561620
Lead Sponsor	Fudan University
Conditions	3-year Disease-free Survival
Enrollment	592 participants
Start Date	2024-05-01
Primary Completion	2027-05-01 (estimated)
Study Completion	2029-05-01 (estimated)
Updated on ClinicalTrials.gov	2024-08-22